1.
Clin Case Rep
; 10(7): e6116, 2022 Jul.
Article
in English
| MEDLINE
| ID: mdl-35898750
ABSTRACT
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well-tolerated in 62.5% of the patients. Ven/HMA provides a benefit particularly when used in patients without prior HMA exposure.
2.
Enferm Infecc Microbiol Clin
; 24(1): 61-3, 2006 Jan.
Article
in Spanish
| MEDLINE
| ID: mdl-16537066
Subject(s)
Immunocompromised Host , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Lung Diseases/virology , Respiratory Syncytial Virus Infections/complications , Respiratory Syncytial Virus Infections/diagnosis , Aged , Antineoplastic Agents/therapeutic use , Dyspnea , Female , Fever , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Respiratory Syncytial Viruses/isolation & purification , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use
3.
Enferm. infecc. microbiol. clín. (Ed. impr.)
; 24(1): 61-63, ene. 2006. ilus
Article
in Es
| IBECS
| ID: ibc-043387
ABSTRACT
No disponible